Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anakinra or tocilizumab alone or with ruxolitinib in severe COVID-19 (stage 2b/3)
2020-001754-21Phase 3Terminated
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Apr 2020
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of anakinra, tocilizumab and ruxolitinib in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Assistance Publique-Hôpitaux de Marseille. Primary endpoint: Ventilation-free days at day 28 (VFD28). Started Apr 2020; status: terminated.
02
Drugs
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001754-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001754-21.